Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immunzellkalender 2025
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English (UK)
Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS
MS Treatments
Jahr
Publikationsjahr
2020
Autoren
Autorenliste der Publikation
Moser T, Schwenker K, Seiberl M, Feige J, Akgün K, Haschke-Becher E, Ziemssen T, Sellner J.
Verlag
Publisher-Information
Ann Clin Transl Neurol. 2020 Nov;7(11):2199-2212.
Link
Zur Publikation (externer Server)
https://doi.org/10.1002/acn3.51206
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Treatments
2020
Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
NIL
Jahr
2025
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study
MS Treatments
Jahr
2025
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS
MS Treatments
Jahr
2025
A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?
MS Treatments
Jahr
2025
Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study
MASC
Jahr
2025
